Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda reports positive Entyvio data for ulcerative colitis and Crohn’s disease

Takeda reports positive Entyvio data for ulcerative colitis and Crohn’s disease

17th October 2017

Takeda has announced new clinical study data showing the quick response its drug Entyvio can deliver in ulcerative colitis and Crohn's disease patients.

Post-hoc analyses of data from the GEMINI clinical trial programme have offered evidence of early symptomatic improvement in specific symptoms with Entyvio in patients with moderate to severely active ulcerative colitis or Crohn's disease, particularly in biologic-naive patients for whom other therapies have not proven effective.

Significant improvements were associated with Entyvio in terms of rectal bleeding and stool frequency in ulcerative colitis, and in terms of abdominal pain and the number of liquid or very soft stools in those with Crohn's.

Some biologic-naive patients were shown to experience notably improved performances over placebo compared to the overall treatment group as early as week two.

Dr Karen Lasch, medical head for gastrointestinal conditions at Takeda's US medical office, said: "Takeda remains committed to contributing to research that helps patients and providers make informed treatment decisions and achieve treatment goals."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.